Engrafted human cells generate adaptive immune responses to Mycobacterium bovis BCG infection in humanized mice

BMC Immunology

Volumn 14, Issue 1, 2013, Pages

  Lee, Jinhee ^a   Brehm, Michael A ^a   Greiner, Dale ^a   Shultz, Leonard D ^b   Kornfeld, Hardy ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

Animal model; BCG; BLT mice; NSG mice; Tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINE; CONTROLLED STUDY; CYTOKINE RELEASE; ENGRAFTMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; GRANULOMA; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; LUNG ALVEOLUS MACROPHAGE; LUNG LESION; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; SPLEEN CELL; TUBERCULOSIS; BOVINE TUBERCULOSIS; IN VIVO STUDY; INFECTION SENSITIVITY; INNATE IMMUNITY; MACROPHAGE; MOLECULAR RECOGNITION; MYCOBACTERIUM BOVIS BCG;

ADAPTIVE IMMUNITY; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HETEROGRAFTS; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LUNG; MACROPHAGES; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICE, TRANSGENIC; MYCOBACTERIUM BOVIS; TUBERCULOSIS;

EID: 84889019058     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-14-53     Document Type: Article

References (45)

1. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013
2. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001, 19:93-129. 10.1146/annurev.immunol.19.1.93, 11244032.
3. Fortin A, Abel L, Casanova JL, Gros P. Host genetics of mycobacterial diseases in mice and men: forward genetic studies of BCG-osis and tuberculosis. Annu Rev Genomics Hum Genet 2007, 8:163-192. 10.1146/annurev.genom.8.080706.092315, 17492906.
4. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104. 10.1056/NEJMoa011110, 11596589.
5. North RJ, Jung YJ. Immunity to tuberculosis. Annu Rev Immunol 2004, 22:599-623. 10.1146/annurev.immunol.22.012703.104635, 15032590.
6. Capuano SV, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, et al. Experimental mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. Tuberculosis infection. Infect Immun 2003, 71:5831-5844. 10.1128/IAI.71.10.5831-5844.2003, 201048, 14500505.
7. Saunders BM, Cooper AM. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol 2000, 78:334-341. 10.1046/j.1440-1711.2000.00933.x, 10947857.
8. Greiner DL, Hesselton RA, Shultz LD. SCID mouse models of human stem cell engraftment. Stem Cells 1998, 16:166-177. 10.1002/stem.160166, 9617892.
9. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005, 174:6477-6489.
10. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006, 12:1316-1322. 10.1038/nm1431, 17057712.
11. Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 2009, 83:7305-7321. 10.1128/JVI.02207-08, 2704767, 19420076.
12. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK, et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007, 204:705-714. 10.1084/jem.20062411, 2118553, 17389241.
13. Van DR, Pedati C, Guendel I, Carpio L, Kehn-Hall K, Saifuddin M, et al. The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology 2009, 6:76. 10.1186/1742-4690-6-76, 2743631, 19674458.
14. Brehm MA, Shultz LD, Greiner DL. Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes 2010, 17:120-125. 10.1097/MED.0b013e328337282f, 2892284, 20150806.
15. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007, 7:118-130. 10.1038/nri2017, 17259968.
16. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 2012, 12:786-798. 10.1038/nri3311, 3749872, 23059428.
17. Calderon VE, Valbuena G, Goez Y, Judy BM, Huante MB, Sutjita P, et al. A humanized mouse model of tuberculosis. PLoS One 2013, 8:e63331. 10.1371/journal.pone.0063331, 3656943, 23691024.
18. Heuts F, Gavier-Widen D, Carow B, Juarez J, Wigzell H, Rottenberg ME. CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria. Proc Natl Acad Sci USA 2013, 110:6482-6487. 10.1073/pnas.1219985110, 3631626, 23559373.
19. Sousa RE. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol 2004, 16:21-25. 10.1016/j.coi.2003.11.007, 14734106.
20. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998, 392:245-252. 10.1038/32588, 9521319.
21. Sambandamurthy VK, Derrick SC, Jalapathy KV, Chen B, Russell RG, Morris SL, et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun 2005, 73:1196-1203. 10.1128/IAI.73.2.1196-1203.2005, 547051, 15664964.
22. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773. 10.1126/science.1123933, 16497887.
23. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004, 119:753-766. 10.1016/j.cell.2004.11.038, 15607973.
24. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S, et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 2011, 3:104ra102. 3269210, 21998409.
25. Kaufmann SH. How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol 2001, 1:20-30. 10.1038/35095558, 11905811.
26. Mogues T, Goodrich ME, Ryan L, LaCourse R, North RJ. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2001, 193:271-280. 10.1084/jem.193.3.271, 2195922, 11157048.
27. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993, 178:2243-2247. 10.1084/jem.178.6.2243, 2191280, 8245795.
28. Bellamy R. Interferon-gamma and host susceptibility to tuberculosis. Am J Respir Crit Care Med 2003, 167:946-947. 10.1164/rccm.2301005, 12663334.
29. Repasy T, Lee J, Marino S, Martinez N, Kirschner DE, Hendricks G, et al. Intracellular bacillary burden reflects a burst size for mycobacterium tuberculosis in vivo. PLoS Pathog 2013, 9:e1003190. 10.1371/journal.ppat.1003190, 3578792, 23436998.
30. Flynn JL, Chan J, Lin PL. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol 2011, 4:271-278. 10.1038/mi.2011.14, 3311958, 21430653.
31. Orme IM, Cooper AM. Cytokine/chemokine cascades in immunity to tuberculosis. Immunol Today 1999, 20:307-312. 10.1016/S0167-5699(98)01438-8, 10379048.
32. Lee J, Remold HG, Ieong MH, Kornfeld H. Macrophage apoptosis in response to high intracellular burden of Mycobacterium tuberculosis is mediated by a novel caspase-independent pathway. J Immunol 2006, 176:4267-4274.
33. Saunders BM, Frank AA, Orme IM, Cooper AM. CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 2002, 216:65-72. 10.1016/S0008-8749(02)00510-5, 12381351.
34. Wiktor-Jedrzejczak W, Gordon S. Cytokine regulation of the macrophage (M phi) system studied using the colony stimulating factor-1-deficient op/op mouse. Physiol Rev 1996, 76:927-947.
35. Rutherford MS, Witsell A, Schook LB. Mechanisms generating functionally heterogeneous macrophages: chaos revisited. J Leukoc Biol 1993, 53:602-618.
36. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002, 99:111-120. 10.1182/blood.V99.1.111, 11756160.
37. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 2004, 14:628-638. 10.1016/j.tcb.2004.09.016, 15519852.
38. Hubel K, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis 2002, 185:1490-1501. 10.1086/340221, 11992286.
39. Akagawa KS. Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages. Int J Hematol 2002, 76:27-34. 10.1007/BF02982715, 12138892.
40. Nemunaitis J. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 1998, 26:1279-1281. 10.1086/516363, 9636846.
41. Tanaka S, Saito Y, Kunisawa J, Kurashima Y, Wake T, Suzuki N, et al. Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rgammaKO mice. J Immunol 2012, 188:6145-6155. 10.4049/jimmunol.1103660, 3370073, 22611244.
42. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994, 91:5592-5596. 10.1073/pnas.91.12.5592, 44042, 8202532.
43. Wada H, Noguchi Y, Marino MW, Dunn AR, Old LJ. T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice. Proc Natl Acad Sci USA 1997, 94:12557-12561. 10.1073/pnas.94.23.12557, 25037, 9356488.
44. Gonzalez-Juarrero M, Hattle JM, Izzo A, Junqueira-Kipnis AP, Shim TS, Trapnell BC, et al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol 2005, 77:914-922. 10.1189/jlb.1204723, 15767289.
45. Brehm MA, Cuthbert A, Yang C, Miller DM, Diiorio P, Laning J, et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol 2010, 135:84-98. 10.1016/j.clim.2009.12.008, 2835837, 20096637.